Safety and reactogenicity
From 0 to 28 days post vaccination, AEs were reported in all cohorts, in both treatment arms. Eighty-three subjects that received BK-SE36/CpG (n = 83/91, 91%) had 334 AEs, of which 119 AEs from 35 subjects (38%) were related to vaccination (